Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France.
HIFIH Laboratory, SFR ICAT 4208, Angers University, Angers, France.
Nat Commun. 2023 Aug 26;14(1):5219. doi: 10.1038/s41467-023-40328-4.
Unlike for advanced liver fibrosis, the practical rules for the early non-invasive diagnosis of cirrhosis in NAFLD remain not well defined. Here, we report the derivation and validation of a stepwise diagnostic algorithm in 1568 patients with NAFLD and liver biopsy coming from four independent cohorts. The study algorithm, using first the elastography-based tests Agile3+ and Agile4 and then the specialized blood tests FibroMeter and CirrhoMeter, provides stratification in four groups, the last of which is enriched in cirrhosis (71% prevalence in the validation set). A risk prediction chart is also derived to allow estimation of the individual probability of cirrhosis. The predicted risk shows excellent calibration in the validation set, and mean difference with perfect prediction is only -2.9%. These tools improve the personalized non-invasive diagnosis of cirrhosis in NAFLD.
与先进的肝纤维化不同,NAFLD 早期肝硬化的非侵入性诊断实用规则仍未明确界定。在这里,我们报告了在来自四个独立队列的 1568 名 NAFLD 患者和肝活检中逐步诊断算法的推导和验证。该研究算法首先使用基于弹性成像的 Agile3+和 Agile4 检测,然后使用专门的血液检测 FibroMeter 和 CirrhoMeter,将患者分为四组,最后一组富含肝硬化(验证组中的患病率为 71%)。还衍生了一个风险预测图表,以允许估计个体肝硬化的概率。该预测风险在验证组中具有出色的校准度,与完美预测的平均差异仅为-2.9%。这些工具可改善 NAFLD 患者肝硬化的个性化非侵入性诊断。